Novartis is also rapidly increasing its business footprint in India making India its biggest global R&D center outside Switzerland. The Swiss firm has a workforce exceeding 9,000 employees in Hyderabad and Mumbai. This is a significant change...
.png "Lupin Achieves Key CHMP Milestone for Ranibizumab Biosimilar")
Lupin Limited, a global pharma company, announced today that the Committee for Medicinal Products to Human Use (CHMP) of the European Medicines Agency had given a positive opinion. The opinion suggests that Lupin marketing authorization be...
Bristol Myers Squibb has launched Mosaic AI content hub, a first-of-its-kind, AI-powered platform designed to reshape how pharmaceutical content is created and delivered. Developed with Accenture, the new hub marks a major step forward in...
The summit commenced with a welcome address by Rajesh Khubchandani, Co-Founder & Managing Director, Team Marksmen Network, who emphasized, “As we start this journey, we have seen a lot of narratives and stories being told. The way a select few organi
Odisha has declared a policy on drugs and medical equipment to bring investments of 25000 crore by 2030. The policy reflects the desire of the state in turning into a large life-sciences hub in eastern India. It was unveiled during the Odisha...
Biocon Biologics Limited, an integrated global biopharmaceutical group and a subsidiary of Biocon Limited have been named under IAM (Intellectual Asset Management). IAM is a leader in international intellectual property publications, to Biocon...
Glenmark Specialty S.A. (GSSA), a wholly owned subsidiary of Glenmark Pharmaceuticals, has signed an exclusive licensing and distribution agreement with Jiangsu Hansoh Pharmaceutical Group. The agreement is for Aumolertinib, a third-generation...
Lupin, a global pharmaceutical company, is making a substantial move towards sustainability. The Science Based Targets initiative (SBTi) certified its greenhouse gas reduction plan, and includes Scope 1, Scope 2, and Scope 3 emissions...
Sanofi said today that tolebrutinib failed to meet its primary endpoint in the PERSEUS phase 3 study in people with primary progressive multiple sclerosis (PPMS), a form of the disease that affects about 10% of the overall MS population...
.jpeg "Akums Strengthens PHN Treatment with Gabapentin ER Launch")
Akums launches an enhanced Gabapentin ER for postherpetic neuralgia, using sustained-release technology to improve pain control, once-daily dosing and patient adherence in India.
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")